A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

NCT05972993 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: mRNA-CR-04 vaccine 10μg
BIOLOGICAL: mRNA-CR-04 vaccine 30μg
BIOLOGICAL: mRNA-CR-04 vaccine 100μg
DRUG: Placebo
BIOLOGICAL: mRNA-CR-04 vaccine 3μg

Sponsor

GlaxoSmithKline